Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kush Goyal

Pain Medicine Cleveland, OH Medical Doctor

NPI 1679777528 CMS profile 809476

1730 W 25Th St # 2C, Center For Spine Health- Lutheran Hospital, Cleveland, OH 44113

Open in the dashboard

General payments

$21,882

106 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kush Goyal of Cleveland, OH is reported in the CMS Open Payments database as having received $21,882 across 106 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,846 17
2024 General $5,597 26
2023 General $12,682 33
2022 General $500 9
2021 General $235 9
2020 General $160 3
2019 General $863 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kush Goyal
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Kush Goyal were reported at $1,846. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Kush Goyal Pain Medicine median Middle half National median
2019 $863 $409 $115–$1,311 $163
2020 $160 $214 $66–$666 $114
2021 $235 $299 $84–$899 $132
2022 $500 $335 $103–$1,149 $149
2023 $12,682 $376 $114–$1,228 $160
2024 $5,597 $387 $115–$1,173 $164
2025 $1,846 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. SI-BONE, Inc. $17,919 47 payments
  2. Boston Scientific Corporation $946 4 payments
  3. SPR Therapeutics, Inc $465 10 payments
  4. Nevro Corp. $380 3 payments
  5. MML US, Inc. $360 6 payments
  6. Radius Health, Inc. $241 2 payments
  7. Stryker Corporation $230 8 payments
  8. Relievant Medsystems, Inc. $202 4 payments
  9. Avanos Medical $191 3 payments
  10. Globus Medical, Inc. $154 1 payment
  11. Other $795 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $14,400 12 payments
  2. Food and Beverage $4,978 81 payments
  3. Travel and Lodging $2,503 13 payments
Products named General payments · program years 2019–2025
  1. IFUSE IMPLANT SYSTEM sacroiliac joint dysfunction $11,567 15 payments
  2. IFUSE IMPLANT SYSTEM sacroiliac joint dysfunction $4,974 11 payments
  3. SPRINT PNS System $465 10 payments
  4. ReActiv8 $360 6 payments
  5. SPECTRA WAVEWRITER $291 1 payment
  6. Senza $265 2 payments
  7. Tymlos $241 2 payments
  8. Intracept $168 3 payments
  9. SPINEJACK $165 6 payments
  10. EXCELSIUS GPS $154 1 payment
  11. Other $1,474 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

439

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$5,131

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

5.7%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 118 $1,516
Pregabalin Generic 45 $954
Celecoxib Generic 22 $694
Diclofenac Sodium Generic 20 $389
Lidocaine Generic 11 $350
Meloxicam Generic 74 $348
Tizanidine Hcl Generic 42 $306
Baclofen Generic 30 $262
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 25 $138
Tramadol Hcl Generic 24 $122

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$44,616

Medicare's payments for the services billed

Medicare patients

282

Average age 72

Services billed

705

172 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 32%
Ischemic heart disease 29%
Diabetes 27%
Cancer 22%
Chronic kidney disease 21%
Osteoporosis 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

106 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record